Drug Safety

      safety data
      Upadacitinib: revisiting safety data in RA and GCA
      6 days 12 hours ago
      For the last several years, conversations about JAK inhibitors have often started and ended with safety. The shadow cast by ORAL Surveillance has made clinicians more cautious and regulators more restrictive. Yet in practice, many of us continue to reach for upadacitinib when we face challenges in treatment, from rheumatoid arthritis to axial spondyloarthritis. 
      #ACR25 Abstr#LB14 Promising therapyBMS-986353, a CD19 CAR-T in Severe Refractory Idiopathic Inflammatory Myopathies. 11

      Md Yuzaiful Md Yusof Yuz6Yusof

      6 days 13 hours ago

      #ACR25 Abstr#LB14 Promising therapy BMS-986353, a CD19 CAR-T in Severe Refractory Idiopathic Inflammatory Myopathies. 11/12 had evaluable data; muscle, skin and ILD improved. 1 x G2 CRS, 1 G3 ICANS. Longer FU needed and larger sample @RheumNow https://t.co/zAG23tAsbL

      Cohort study comparing 3yr safety outcomes of JAKi vs. TNFi in AS pts

      JAKi use: ⬆️incidence of HZ infxn but not sig

      sheila RHEUMarampa

      1 week ago
      Cohort study comparing 3yr safety outcomes of JAKi vs. TNFi in AS pts JAKi use: ⬆️incidence of HZ infxn but not significant; ⬆️all-cause mortality (HR 4.94) and GI bleed (p=0.04) Individualize tx. consider potential complications #ACR25 @RheumNow Abs2633 https://t.co/pjKAazQFwW
      Sex differences in 💊 d/c in axSpA from the RISE registry

      🔅Females - ⬆️discontinuation risks for TNFi
      🔅No

      sheila RHEUMarampa

      1 week ago
      Sex differences in 💊 d/c in axSpA from the RISE registry 🔅Females - ⬆️discontinuation risks for TNFi 🔅No sex differences seen in dc risks for IL17i and JAKis 🔅Young females discontinued faster than males Gender diff in SpA can guide tx decisions #ACR25 @RheumNow Abs2634 https://t.co/kcXfZrU4zI
      We often see patients with MTX lab abnormalities but How frequent is MTX toxicity?

      Retrospective study 2500pts
      Rocheste

      Aurelie Najm AurelieRheumo

      1 week ago
      We often see patients with MTX lab abnormalities but How frequent is MTX toxicity? Retrospective study 2500pts Rochester Epidemiology Project cohort 60% w/ ever lab abnormalities, but 4% attributed to MTX 0.87/100 patient year Organ injury event 0.02/100 patient year = 5 in https://t.co/w8oYUjj5Yp
      Head to head study of Secukinumab vs Ustekinumab. In TNFi-experienced PsA patients, the AgAIN trial shows secukinumab pe

      Antoni Chan MD (Prof) synovialjoints

      1 week ago
      Head to head study of Secukinumab vs Ustekinumab. In TNFi-experienced PsA patients, the AgAIN trial shows secukinumab performed better than ustekinumab in HAQ-DI response (57.1% vs 27.0%, p=0.002) and across all endpoints (joint counts, pain, and skin outcomes). Fewer https://t.co/CDCWkLF5TW
      Abstract 2360: Single-center lupus pregnancy cohort found that:
      🔹 Absence of DORIS remission associated w/ adverse pr

      Akhil Sood MD, MS AkhilSoodMD

      1 week ago
      Abstract 2360: Single-center lupus pregnancy cohort found that: 🔹 Absence of DORIS remission associated w/ adverse pregnancy outcomes (Pre-term, Pre-eclampsia) 🔹 This is along with known risk factors: antihypertensive use, prior nephritis, active disease @RheumNow #ACR25 https://t.co/STg1NBeFPo
      In a retrospective TrinetX analysis of 3 year safety outcome in AS, JAKi use was linked to higher mortality and GI bleed

      Antoni Chan MD (Prof) synovialjoints

      1 week ago
      In a retrospective TrinetX analysis of 3 year safety outcome in AS, JAKi use was linked to higher mortality and GI bleeding vs TNFi, but lower malignancy risk. Infection rates were similar, with a trend toward more herpes zoster in JAKi users. Abstract#2633 @RheumNow #ACR25 https://t.co/pPY0wpAKA3
      DMARD exposure overall during pregnancy is not associated with severe maternal or neonatal morbidity, in this Ontario co

      David Liew drdavidliew

      1 week ago
      DMARD exposure overall during pregnancy is not associated with severe maternal or neonatal morbidity, in this Ontario cohort. We’re getting better at finding a balance with DMARDs that is safe for both mother and baby. Blanket resistance is harmful #ACR25 ABST2627 @RheumNow https://t.co/oDOpySGS3N
      Predictors of retinopathy progression after HCQ discontinued?

      In the chart review of 28 pt records who had retinopathy,

      sheila RHEUMarampa

      1 week ago
      Predictors of retinopathy progression after HCQ discontinued? In the chart review of 28 pt records who had retinopathy, 35% progressed despite d/c Age - significant assoc'n with progression ✳️monitor toxicity more closely esp in older pts #ACR25 @RheumNow Abs2444 https://t.co/9rf2RQAgRQ
      A new IA drug in OA 🚨

      Cell therapy of apoptotic PBMCs ENX-CL-05-001
      RCT Ph2A moderate to severe OA
      134 pts 3 injecti

      Aurelie Najm AurelieRheumo

      1 week ago
      A new IA drug in OA 🚨 Cell therapy of apoptotic PBMCs ENX-CL-05-001 RCT Ph2A moderate to severe OA 134 pts 3 injections vs. PBO Pain improvement 24% Better response in people > 60 and more so 65yo Potential improvement for > 6mo Safety mainly local reactions to compound https://t.co/m2MZN3i22b
      Post-hoc analysis of CARE study comparing effect of Cenerimod 4mg vs. PBO

      Mos. 4-6: >10% improvement in alopecia w/

      sheila RHEUMarampa

      1 week ago
      Post-hoc analysis of CARE study comparing effect of Cenerimod 4mg vs. PBO Mos. 4-6: >10% improvement in alopecia w/Cenerimod Mos. 2-6: >10% improvement in mucosal ulcers w/ Cenerimod Early improvement in alopecia & ulcers w/Cenerimod Promising? #ACR25 @RheumNow Abs2440 https://t.co/mAqmIQashr
      52wks data of IZOKIPEB affibody IL17Ai RCT 2b/3 PsA

      Primary ACR 50 16wks
      Crossover 52 wks IZO 160 Q2W, IZO 160 QW, PBO-

      Aurelie Najm AurelieRheumo

      1 week ago
      52wks data of IZOKIPEB affibody IL17Ai RCT 2b/3 PsA Primary ACR 50 16wks Crossover 52 wks IZO 160 Q2W, IZO 160 QW, PBO-> IZO 160 QW ACR50 50% 57% 51% ACR70 36% 42% 42% PASI100 55% 64% 58% MDA 47% 52% 47% No specific enthesitis data presented No new safety signal Next https://t.co/J18rSTmyze
      Safety of CAR-T
      1 week ago
      #1748 Higher air pollution, esp PM2.5, linked to ⬆️RA disease activity and more flares in >1000 Korean patients.

      Mrinalini Dey DrMiniDey

      1 week ago
      #1748 Higher air pollution, esp PM2.5, linked to ⬆️RA disease activity and more flares in >1000 Korean patients. Each rise in PM2.5 significantly boosted DAS28, CDAI & joint counts. Does cleaner air mean calmer joints? @RheumNow #ACR25

      Podcasts

      • ACR 2025 Daily Podcasts Day2d

      Catch up on Conference Podcasts

      ×